Cerebral Infarction Drugs Market Share

  • Report ID: 3382
  • Published Date: Nov 20, 2025
  • Report Format: PDF, PPT

Cerebral Infarction Drugs Market - Regional Analysis

North American Market Insights

The North America industry is poised to hold largest revenue share of 50% by 2035. The growth of the market can be attributed majorly to the increasing frequency of cerebrovascular disease amongst several people, backed by the sedentary lifestyle of individuals. For instance, the fifth most common cause of mortality in the United States and the most frequent type of brain injury that poses a serious risk to life is a cerebrovascular disease which contributed to more than 168,000 deaths in 2020. In addition, the region's escalating healthcare industry, and rising proportion of obesity, and hypertension rates in the population of the United States and Canada are also anticipated to boost the market growth during the forecast period. In addition to this, the increasing approval for novel drug delivery systems and treatments is another significant factor that is projected to further boost the market growth in the region during the projected time frame.

APAC Market Insights

The Asia Pacific cerebral infarction drugs market, amongst the market in all the other regions, is projected to hold the second largest share of about 20% during the forecast period. The growth of the market can be attributed majorly to the rising geriatric population, and the advancing healthcare system. Based on the statistics of the World Bank, the population above 65 years of age in India crossed 90,719,952 in 2020, while, it crossed 167,808,567 in China. Moreover, rising healthcare expenditure and surging investment in R&D activities is also estimated to boost the market growth further throughout the projected time frame in the APAC region.

Europe Market Insights

Further, the market in the European region, amongst the market in all the other regions, is projected to hold a majority of the share of about 15% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of hypertension, coupled with the escalating prevalence of atherosclerosis among people in the region. Further, the existence of a strong healthcare network in the region, along with the region's expanding healthcare industry, and rise in novel drug developments are also anticipated to boost the market growth during the forecast period. 

Cerebral Infarction Drugs Market share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of cerebral infarction drugs is estimated at USD 9.28 billion.

The global cerebral infarction drugs market size crossed USD 8.64 billion in 2025 and is likely to register a CAGR of over 8.2%, exceeding USD 19 billion revenue by 2035.

North America is poised to hold a 50% share by 2035, driven by the rising prevalence of cerebrovascular disease, sedentary lifestyles, and increasing approvals for novel drug delivery systems.

Key players in the market include Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Edwards Lifesciences Corporation, Daiichi Sankyo Company, Limited.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos